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SIGN-R1, a recently discovered C-type lectin expressed at high levels
on macrophages within the marginal zone of the spleen, mediates the
uptake of dextran polysaccharides by these phagocytes. We now find
that encapsulated Streptococcus pneumoniae are rapidly cleared by
these macrophages from the bloodstream, and that capture also
takes place when different cell lines express SIGN-R1 after transfec-
tion. To assess the role of the capsular polysaccharide of S. pneu-
moniae (CPS) in the interaction of SIGN-R1 with pneumococci, we first
studied binding and uptake of serotype 14 CPS in transfected cells.
Binding was observed and was of a much higher avidity (3,000-fold)
for CPS 14 than dextran. The CPSs from four different serotypes were
also cleared by marginal zone macrophages in vivo. To establish a role
for SIGN-R1 in this uptake, we selectively down-regulated expression
of the lectin by pretreatment of the mice with SIGN-R1 antibodies,
including a newly generated hamster monoclonal called 22D1. For
several days after this transient knockout, the marginal zone macro-
phages were unable to take up either CPSs or dextrans. Therefore,
marginal zone macrophages in mice have a receptor that interacts
with capsular pneumococcal polysaccharides, setting the stage for
further studies of the functional consequences of this interaction.
The spleen functions at several points in innate and adaptiveimmunity. A major innate function is exerted by macro-
phages that are abundant in vascular regions termed the splenic
red pulp, whereas adaptive functions are carried out by B and T
lymphocytes, typically located in white pulp nodules. At the
junction of each white pulp nodule with the red pulp is a
specialized region called the marginal zone, which is composed
of several concentric regions (1). Innermost is a ring of macro-
phages termed marginal metallophils, expressing a hemaggluti-
nin termed sialoadhesin or CD169 (2, 3). Then there is a vascular
sinus that receives blood via penetrating small arterial vessels
from the white pulp. Surrounding the marginal sinus is a zone
composed of large macrophages as well as specialized B lym-
phocytes (4). Within and surrounding the marginal zone are also
dendritic cells (5, 6), possibly in the process of migrating from the
blood to the T cell regions of the white pulp.
With respect to host defense, the spleen plays a special role
during blood-borne infection with encapsulated microorgan-
isms, particularly Streptococcus pneumoniae bacteria (7–12). A
critical role of the spleen is the formation of antibodies by
marginal zone B cells (13–15), particularly complement-fixing
antibodies (16–20). The role of macrophages in the processes of
microbial clearance and resistance and antibody formation to S.
pneumoniae needs to be considered (21), particularly given
recent data that marginal zone macrophages interact and retain
B cells in this region (22). Here we show that marginal zone
macrophages express a receptor called SIGN-R1 that is able to
bind and internalize the capsular pneumococcal polysaccharide
(CPS). SIGN-R1 is a C-type lectin that is a member of a recently
identified family related to DC-SIGN (23). It was recently
reported that SIGN-R1 is expressed at high levels in marginal
zone macrophages of the spleen, as well as other macrophages
in the lymph node (24, 25). Furthermore, SIGN-R1 mediates the
clearance of the polysaccharide dextran in vivo (24, 25). We
therefore asked whether SIGN-R1 also was involved in the
uptake of pneumococci and its capsular polysaccharide. We find
that this is the case, and that CPS uptake can be eliminated in
mice that are selectively depleted of SIGN-R1 by treatment with
specific antibody to this lectin.
Methods
Mice and Cell Culture. C57BL6 mice from The Jackson Laboratory
were kept under specific pathogen-free conditions until use at 6–10
weeks of age. All experiments were conducted according to insti-
tutional guidelines. Chinese hamster ovary (CHO) and OKT8 cells
Abbreviations: CPS, capsular polysaccharide of S. pneumoniae; TKO, transient knockout;
CHO, Chinese hamster ovary.
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Fig. 1. The lectin SIGN-R1 mediates the uptake of encapsulated S. pneu-
moniae. (A) Mice were injected i.v. with 108 fluorescent (red, PKH26) organ-
isms after 100 g of FITC-dextran i.v. injection for 1 h, the latter to label
SIGN-R1 marginal zone macrophages as described (24, 25). (B) CHO cells
transfected with control (neomycin) DNA or with SIGN-R1 cDNA were chal-
lenged for 1 h with live, mitomycin-treated, or heat-treated S. pneumoniae
serotype 3 (1,000,000 green organisms per 10,000 cells), and uptake was
assessed alongside a 4,6-diamidino-2-phenylindole (blue) nuclear label.









were cultured in DMEM with 10% FCS100 units/ml penicillin
G100 g/ml streptomycin. DCEK, a mouse L cell fibroblast line,
was cultured in RPMI medium 1640 with 10% FCS and antibiotics.
Stable CHO transfectants expressing cDNAs of mouse SIGN-R1,
DC-SIGN, SIGN-R3, and DEC205 were generated as described
(25) and cloned under G418 (1.5 mgml) selection pressure. Stable
OKT8 and DCEK SIGN-R1 transfectants were generated by using
a pMX retroviral vector (26) as described (27).
Antibodies and Microscopy. A soluble SIGN-R1 antigen of fusion
between the extracellular portion of SIGN-R1 and mouse IgG Fc
was produced, affinity purified from transfected mammalian
cells, and used as antigen to generate a new hamster monoclonal
antibody, 22D1, in the Hybridoma Core Facility at Mt. Sinai
School of Medicine. Rabbit polyclonal antibodies against the
C-terminal 13-aa peptide of SIGN-R1 (PAb-C13) were de-
scribed (25). Similarly, rabbit polyclonal antibodies against the
16-aa peptide of mouse DC-SIGN (NH2–FRDDGWNDTKCT-
NKKF-COOH) and SIGN-R3 (NH2–FSGDGWDLSCDKLLF–
COOH) carbohydrate recognition domains were generated by
Invitrogen, as described (25). Antibodies to DEC205 (CD205),
I-A (MHC II), sialoadhesin (CD169), and F480 were purified
from the supernatants of the NLDC-145, KL295, SER-4, and
F480 hybridomas (25). Antibodies to the following targets were
purchased: Actin (Abcam, Cambridge, MA), SIGN-R1 [ER-
TR9 (28), BMA Biomedicals], MARCO [ED31 (29), Serotec],
transferrin receptor (C2F2, BD Biosciences PharMingen), and
IgM (Southern Biotechnology Associates). Serotype-specific
polyclonal rabbit antibodies to pneumococcal polysaccharides
were purchased from Statens Serum Institute (Copenhagen). A
deconvolution microscope (Olympus, Melville, NY) and one-,
two-, or three-color fluorescence labeling were used.
SDSPAGE and Western Blot Analysis. Spleens were lysed in RIPA
buffer (150 mM NaCl50 mM TrisHCl, pH 8.01% Nonidet
P-400.5% sodium deoxycholate0.1% SDS) supplemented with
protease inhibitor cocktails (Sigma) and stored at 80°C. Each
lysed sample was mixed with an equal volume of 2 SDS sample
buffer with 2-mercaptoethanol and boiled at 95°C for 5 min. The
samples of lysate were separated in 4–15% gradient SDSPAGE,
transferred onto poly(vinylidene difluoride) membranes, followed
by incubation with antibodies. Antibody-reactive bands on the blots
were visualized with peroxidase-labeled secondary antibodies fol-
lowed by ECLplus chemiluminescent substrate (Amersham Phar-
macia Biosciences) and exposure in Kodak BioMax Light film
(Eastman Kodak).
Polysaccharides. FITC-Ficoll (Biosearch) and CPSs of various
serotypes (American Type Culture Collection, Manassas, VA)
were purchased. The following materials were purchased from
Sigma: FITC-dextran (2,000 kDa), dextran (2,000 kDa), and
Ficoll (400 kDa). To study endocytosis of these polysaccharides
in vivo, 100 g per mouse was administered i.v. and uptake
studied from 1 to 24 h later; alternatively, the polysaccharides
were added in vitro at 1–50 gml for 1–2 h on ice or at 37°C to
cell lines transfected with SIGN-R1, and mDC-SIGN or empty
vector as negative control. To test for inhibition of uptake, we
Fig. 2. SIGN-R1 mediates the uptake of the capsular polysaccharide of S. pneumoniae. (A) Both FITC-dextran (green) and CPS 14 (red) are taken up by
SIGN-R1-transfected DCEK cells but not by mouse DC-SIGN transfectants. The white arrow (Lower Right) illustrates extensive double labeling of CPS14 and
FITC-dextran in endocytic vacuoles. (B) As in A, but the polysaccharides were applied at 4°C to assess binding to the cell surface. (C) CPS14 (pretreatment at 100
gml for 30 min at 37°C) but not cold dextran or NP-ficoll (both at 500 gml) blocked uptake of FITC-dextran, given for 1 h at 1 gml. (D) Graded doses of
each of the indicated polysaccharides were added for 30 min before and 1 h during exposure to 1 gml FITC-dextran.
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used 100 g of antibody per animal given i.v. before injecting 100
g of FITC-dextran or CPSs.
S. pneumoniae Strains and Fluorescent Labeling. S. pneumoniae
capsular type 3 (DCC1714) and 14 (DCC1490) were grown in
Brain Heart Infusion broth (Difco) to midlogarithm phase and
inactivated with 50 gml mitomycin-C (Sigma) for 1 h or heat
killed by incubation at 95°C for 10 min, which removes the
capsule. These bacteria were labeled with the PKH2 (green) or
PKH26 (red) fluorescent cell linker kits (Sigma). Suspensions of
109 bacteria per milliliter were incubated at 25°C for 10 min in
a diluent containing 2 M PKH dyes. After incubation, the
excess of fluorescent dye was removed by extensive washing in
PBS. The fluorescent bacteria (1  108) were given i.v., and
mouse spleen sections were examined by deconvolution fluo-
rescence microscopy.
FACS Analysis and Inhibition Experiments. Transfected CHO cells
were incubated with antibodies for 30 min, washed, and incu-
bated with secondary antibodies, followed by analysis with the
FACSCalibur Flow Cytometry System (BD Biosciences). For
FACS analysis of SIGN-R3-transfected CHO cells, we used
incubation with FITC-dextran to verify SIGN-R3 expression,
because the rabbit anti-SIGN-R3 peptide polyclonal antibody
could detect SIGN-R3 molecules only in Western blots and not
FACS. To stain for CPSs, transfectants were permeabilized by
using CytofixCytoperm kit (BD Biosciences PharMingen) be-
fore staining. For inhibition experiments, cells were first incu-
bated for 10 min with varying concentrations of polysaccharides
at 4°C, followed by incubation with 1 gml FITC-dextran at
37°C for 1 h. The percentage of inhibition of FITC-dextran
uptake in the presence of inhibitors was: % Inhibition  {(MFI
of cells stained without inhibitors)(MFI of cells stained with
inhibitors)}  100  (MFI of cells stained without inhibitors)
(MFI, mean fluorescence index).
Results
The Lectin SIGN-R1 Mediates Capture of Encapsulated S. pneumoniae.
We began our studies by following the uptake of encapsulated
fluorescent-labeled S. pneumoniae into the spleen. Thirty min-
utes after injecting 108 mitomycin-treated organisms, the spleens
were sectioned and examined by deconvolution fluorescence
microscopy. The S. pneumoniae were primarily found in the
marginal zone (Fig. 1A). The red fluorescent organisms were
within macrophages, as evidenced by two new criteria (24, 25),
i.e., uptake of the polysaccharide FITC-dextran (Fig. 1 A) or
staining with an antibody to SIGN-R1 (not shown). To test
whether SIGN-R1 was itself involved in microbial uptake, we
exposed SIGN-R1 transfectants to S. pneumoniae in culture at a
multiplicity of 100:1. For both CHO cells (Fig. 1B) and DCEK
cells (not shown), SIGN-R1 transfectants bound encapsulated S.
pneumoniae but not capsule-depleted heated organisms. In
contrast, SIGN-R1 transfectants did not bind Alexa488-labeled
Staphylococcus aureus. To verify the role of SIGN-R1 in the
binding of S. pneumoniae by transfectants, we showed that the
ER-TR9 antibody to SIGN-R1 blocked binding, whereas control
antibody or antibody to the transferrin receptor did not (not
shown). These initial findings indicate that encapsulated S.
pneumoniae are rapidly taken up by SIGN-R1 splenic macro-
phages in situ and captured by SIGN-R1 transfectants in culture.
SIGN-R1 Mediates Uptake of the Capsular Polysaccharide of S. pneu-
moniae. The uptake of encapsulated but not heated organisms in
Fig. 1B suggested that the CPS was being recognized by SIGN-
R1. We therefore studied the uptake by DCEK cells of CPS from
three serotypes, 14, 23, 26. Cells transfected with SIGN-R1 took
up these polysaccharides (Fig. 2A). No uptake was seen in
wild-type cells or cells transfected with three other putative
lectins (DC-SIGN in Fig. 2 A; SIGN-R3 and DEC-205, not
shown). SIGN-R1 also mediated uptake of FITC-dextran (Fig.
2A) as described (24, 25), whereas cells exposed to both dextran
and CPS showed considerable double labeling of the intracel-
lular endocytic compartments (Fig. 2 A Inset). In addition to
these microscopic assays, uptake of CPS14 by SIGN-R1 was
evident with FACS analyses of either DCEK or RAW transfec-
tants (not shown). To directly demonstrate binding to the cell
surface of the transfectants, binding of CPS14 and FITC-dextran
at 4°C was additionally found (Fig. 2B). Interestingly, when we
tried to block uptake of FITC-dextran by using FACS assays,
CPS14 was a much more effective blocker than cold dextran (Fig.
2C). We therefore used this FACS assay to quantify the capacity
of different CPSs (30, 31) to block uptake of FITC-dextran via
SIGN-R1. CPS14 was 3,000 times better in blocking the uptake
of FITC-dextran than dextran itself (Fig. 2D), whereas CPS3 was
50 times better. IC50 values for CPS14, CPS3, and cold dextran
Fig. 3. Isolation of the 22D1 hamster monoclonal antibody to mouse SIGN-
R1. (A) One hundred micrograms of rabbit PAb-C13 to SIGN-R1 or hamster
22D1 monoclonal was injected i.v., and 1 h later the spleen sections were
stained as indicated above each micrograph. (B) Same as A, but SIGN-R1-
transfected OKT8 cells were exposed successively for 30 min to one species
(hamster monoclonal, rabbit polyclonal) of antibody, followed by a second
incubation with the alternative antibody, and then the cells were stained for
binding of hamster Ig (Upper) or rabbit Ig (Lower) to demonstrate that each
anti-SIGN-R1 antibody does not block the binding of the other. (C) Blocking of
FITC-dextran uptake (1 gml for 1 h at 37°C) in OKT8 cells transfected with
SIGN-R1 (blue tracing is the FITC signal from nontransfected cells exposed to
FITC-dextran). The blocking antibodies to SIGN-R1 were rabbit PAb-C13 (and
-mDC-SIGN as a nonreactive control) and hamster 22D1 (and H57–597 to the
T cell receptor as a nonreactive control).









were 0.009, 0.5, and 31 mgml, respectively. These findings
indicate that SIGN-R1 mediates the uptake of several different
CPSs, and among the serotypes we studied, CPS14 was most
effectively recognized.
Isolation of the 22D1 Hamster Monoclonal Antibody to Mouse SIGN-
R1. Two antibodies to SIGN-R1 had been used in prior work to
block the interaction of FITC-dextran with this lectin. One was
a rabbit polyclonal (here termed PAb-C13) to a COOH terminal
13-aa peptide (SIGN-R1 is a type II transmembrane protein),
whereas the other was a commercial rat IgM monoclonal termed
ERTR9 (28). After immunization of hamsters with SIGN-R1
fusion protein, we retrieved a stable monoclonal, named 22D1,
that selectively bound to SIGN-R1 but not to cells transfected
with other lectins (data not shown). The 22D1 antibody also
immunoblotted SIGN-R1 (see below). However, the hamster
antibody recognized a site distinct from the peptide recognized
by rabbit PAb-C13 antibody. For example, if mice were given 100
g of either rabbit or hamster antibody i.v., and 1 h later the
spleens were sectioned and stained for both the injected antibody
or the alternative anti-SIGN-R1, there was clear double labeling,
i.e., the binding of one anti-SIGN-R1 antibody did not block
staining with the other (Fig. 3A). Similar results were obtained
by FACS analysis, i.e., staining with 22D1 did not block staining
with PAb-C13, and staining with PAb-C13 did not block reac-
tivity with 22D1 (Fig. 3B). Polyclonal PAb-C13 was able to block
the uptake of FITC-dextran by SIGN-R1 transfectants, but
neither 22D1 nor antibodies to other lectins was inhibitory (Fig.
3C). Therefore, 22D1 is a distinct monoclonal capable of rec-
ognizing mouse SIGN-R1 but unable to block uptake of the
polysaccharide FITC-dextran by SIGN-R1 transfectants.
Selective and Prolonged Down-Regulation of SIGN-R1 After Injection
of Antibody. We then discovered that the antibodies could be
injected i.v. and used to induce a selective, prolonged, but
transient (5–15 days) down-regulation of SIGN-R1 protein as
assessed by staining of tissue sections and immunoblotting. We
refer to the antibody-treated mice as transient knockouts
(TKOs). As shown in Fig. 4A, we injected mice with 100 g of
control hamster Ig or 22D1 monoclonal antibody, and then 1 day
later, we gave FITC-dextran for 1 h. The 22D1-treated mice
could no longer take up dextran into the marginal zone macro-
phages (Fig. 1 A), although liver uptake was ostensibly unper-
turbed. When the sections were stained for the injected hamster
antibody, or with rabbit PAb-C13 antibody to a second SIGN-R1
epitope (above), no staining was found, indicating that both
SIGN-R1 and the antibody had been down-regulated (Fig. 4A,
second and third rows). The down-regulation of SIGN-R1 was
specific, because other macrophage receptors, Marco and SER4,
were still expressed on marginal zone macrophages and metal-
lophils, respectively (Fig. 4A, fourth and fifth rows). This selec-
tive loss was confirmed by immunoblotting; treatment with
Fig. 4. Selective down-regulation of SIGN-R1 after injection of antibody. (A) Mice were given 100 g of control hamster Ig or 22D1 anti-SIGN-R1 antibody
(similar results were obtained with rabbit PAb-C13 antibody). One day later, mice were given 100 g of FITC-dextran i.v., and 1 h later, the spleens were sectioned
to assess FITC-dextran uptake (Top) or for staining for hamster Ig, SIGN-R1 (with PAb-C13), and the macrophage receptors MARCO and SER4 (CD169, sialoadhesin).
In parallel (Right), samples of spleen tissue were Western-blotted with antibodies to document the selective down-regulation of SIGN-R1. (B) In contrast to A,
mice were first given 100 g of FITC-dextran i.v. and 1 h later 100 g of control hamster Ig or 22D1 anti-SIGN-R1. One day later, the spleens were examined for
the persistence of FITC-dextran in the marginal zone macrophages (green) and the expression of SIGN-R1 (red) by staining with PAb-C13. (C) TKO of SIGN-R1
(green) but not MARCO (red) in macrophages given control Ig or 22D1 hamster monoclonal anti-SIGN-R1 1 day earlier. (Left) The antibody was given i.v. to target
macrophages in spleen. (Right) The hamster antibody was given i.p. to target macrophages in mesenteric lymph nodes.
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SIGN-R1 antibody for 24 h led to the disappearance of the lectin
but not several other molecules in macrophages and other cells
of the spleen (Fig. 4A Right).
To further verify that antibody was depleting SIGN-R1 but not
the respective macrophages, we first allowed the macrophages to
take up FITC-dextran for 1 h, and then we injected control
hamster Ig or 22D1 antibody (Fig. 4B). One day later, we looked
for FITC-dextran and SIGN-R1 by using the rabbit PAb-C13.
Treatment with 22D1 did not eliminate the dextran-laden mac-
rophages but did eliminate the SIGN-R1 (Fig. 4B).
To determine whether antibody could transiently knock out
SIGN-R1 in both spleen and lymph node, we gave mice 100 g
of 22D1 antibody i.v. or 200 g i.p. to access the spleen and
mesenteric lymph nodes, respectively. i.v. injection of antibody
down-regulated SIGN-R1 expression in spleen, not lymph node,
whereas i.p. injection primarily eliminated the lectin from lymph
nodes (Fig. 4C). The elimination of SIGN-R1 persisted for 1
wk. Therefore, antibodies to SIGN-R1 are able to selectively
knock out the lectin, permitting analysis of its function in vivo.
Uptake of Several Serotypes of Capsular Pneumococcal Polysaccha-
ride Is Blocked in Mice Selectively Depleted of SIGN-R1. We first
injected CPS from several different pneumococcal serotypes
(types 3, 14, 23, and 26) i.v., and 30 min later we looked for the
injected CPS in spleen sections. In each case, the CPSs were
noted in abundance in the marginal zone macrophages, double
labeled with PAb-C13 (Fig. 6, which is published as supporting
information on the PNAS web site). At higher power, the CPS14
was located in internal granules within SIGN-R1 macrophages
(Fig. 5A). However, if we injected the 22D1 antibody i.v. 24 h
earlier to create a SIGN-R1 TKO, and then we injected CPS i.v.,
there was no uptake of either FITC-dextran or CPS into the
marginal zone macrophages, but uptake into the liver was
retained (Fig. 5B). To establish the specific role for SIGN-R1 in
CPS uptake in vivo, we injected mice with ED31, a commercial
monoclonal to MARCO, a scavenger receptor also expressed on
SIGN-R1-positive marginal zone macrophages (32). CPS uptake
was blocked only in mice given 22D1 anti-SIGN-R1 but not in
Fig. 5. Uptake of several serotypes of pneumococcal CPS is blocked in mice selectively depleted of SIGN-R1. (A) Mice were injected i.v. with 100 g of CPS from
different serotypes, and 30 min later, the spleens were taken for sectioning and staining for the injected CPS (by using serotype-specific rabbit polyclonal
antibody, ATCC, red) and for SIGN-R1 (rabbit PAb-C13, green) to observe double labeling of the marginal zone macrophages. Here, CPS14 lies within SIGN-R1
macrophages. (B) TKO of SIGN-R1 was induced by injecting 100 g of 22D1 hamster Ig (or nonreactive hamster Ig control), and 24 h later, 100 g of FITC-dextran
(green) or CPS 14 (red) was given i.v. Thirty minutes later, spleen and livers were taken for sectioning and visualization of the injected SIGN-R1 ligands. (C)
Additional mice were injected with a commercial rat IgG1 monoclonal to MARCO (named ED31) or a control polyclonal antibody to the cytosolic domain of mouse
DC-SIGN. Each mouse was given 100 g of CPS 14. Thirty minutes later, we visualized SIGN-R1 (green PAb-C13, Top), MARCO (green mAb, Middle), or the injected
CPS 14 (red polyclonal to CPS14, Bottom).









mice injected with ED31 anti-MARCO antibody (Fig. 5C). We
conclude that antibody to SIGN-R1 selectively down-regulates
this macrophage endocytic receptor for days in vivo, and that this
method reveals SIGN-R1 to be a major receptor for the uptake
of CPS in vivo.
Discussion
Despite the importance of the spleen in defense against encap-
sulated bacteria (7–12), particularly S. pneumoniae, there have
been relatively few studies of the fate of these organisms or the
CPS in vivo. In pioneering studies of the uptake of polysaccha-
rides, primarily dextran, in mouse spleen (33, 34), Humphrey and
Grennan (33) also reported the uptake of CPS in the macro-
phages of the marginal zone and red pulp. Recent investigations
have shown that the marginal zone macrophages express a
C-type lectin, SIGN-R1, that mediates dextran uptake (24, 25).
Here we find that this lectin also contributes to the uptake of all
four different CPS serotypes that we tested. Our work applies to
the early clearance of CPS, 30–60 min after injection. At later
time points, when complement begins to be fixed, the CPS is
found on B cells and the follicular dendritic cells of the B cell
areas, as reported (17, 35), because both cell types express the
CD21 receptors for C3, the third component of complement.
At this time, the consequences of SIGN-R1 function after uptake
of CPS in vivo remain to be determined. Interestingly, a related
C-type lectin, human DC-SIGN, has multiple functions in vitro,
including (i) uptake into processing compartments (36), (ii) seques-
tration within nonlysosomal nonendosomal vacuoles (37, 38), and
(iii) binding to intercellular adhesion molecules on other cells like
ICAM-3 on T cells (39) and ICAM-2 on endothelial cells (40). In
an analogous manner, it will be important to assess whether the CPS
is (i) digested by marginal zone macrophages, (ii) retained in an
intact form available for subsequent presentation to B cells, andor
(iii) involved in interaction with other cells, such as marginal zone
B cells, which are the lymphocytes involved in antibody formation
to polysaccharides (15).
Likewise, the role of SIGN-R1 in the host response to the
intact pneumococcus remains to be determined. Although
SIGN-R1 mediates the uptake of encapsulated organisms (Fig.
1B), we suspect that there are additional recognition systems.
First, when we transiently knock out SIGN-R1 with antibody,
uptake of pneumococci by marginal zone macrophages is still
observed. In addition, uptake of CPS in the TKO mice is
extensive in liver macrophages (Fig. 5B). Conceivably there are
additional receptors that recognize CPS and other pneumococ-
cal cell wall components, such as the peptidoglycan.
An important method devised for our studies was the use of
antibodies to transiently knock out a surface receptor for as long as
1 wk. When we administered a high dose of either monoclonal
hamster antibody or polyclonal rabbit antibody, SIGN-R1 disap-
peared by using staining and immunoblotting methods (Fig. 4A).
The loss of SIGN-R1 was specific, because an antibody to a distinct
epitope on the molecule (hamster antibody 22D1 in the case of
rabbit anti-SR1 TKO and vice versa) was no longer reactive with
SIGN-R1 in vivo, even though the marginal zone macrophage was
still intact, as evidenced by expression of the MARCO endocytic
receptor and retention of preadministered dextran (Fig. 4 A and B).
We do not know whether this method will apply more broadly to
other molecules. SIGN-R1 may be a particularly good candidate for
this TKO approach, e.g., because the receptor when ligated may be
able to traffic digestive lysosomal compartments and because the
turnover of the receptor and of the marginal zone macrophages may
be slow in vivo. These features remain to be determined, but we
anticipate that the TKO method will help to assess the need for
SIGN-R1 in the host response to CPS.
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